Flexion Therapeutics, Inc. (FLXN) News
Filter FLXN News Items
FLXN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FLXN News Highlights
- For FLXN, its 30 day story count is now at 25.
- Over the past 16 days, the trend for FLXN's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- The most mentioned tickers in articles about FLXN are LAW, MDP and ADMS.
Latest FLXN News From Around the Web
Below are the latest news stories about Flexion Therapeutics Inc that investors may wish to consider to help them evaluate FLXN as an investment opportunity.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ECHO, ACBI, HRC, FLXN; Shareholders are Encouraged to Contact the FirmNEW YORK, NY / ACCESSWIRE / November 4, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Echo Global Logistics, Inc. (NASDAQ:ECHO)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds managed by The Jordan Company, L. |
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss MarkPacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year. |
Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call TranscriptJoining me as speakers on today's call are Dave Stack, Chairman and Chief Executive Officer; and Charlie Reinhart, Chief Financial Officer. Before we begin, let me remind you that today's call will include forward-looking statements based on current expectations, including those related to the potential transaction between Pacira and Flexion Therapeutics. |
FLEXION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXNFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Flexion Therapeutics, Inc. (NasdaqGM: FLXN) to Pacira BioSciences, Inc. (NasdaqGS: PCRX). Under the terms of the proposed transaction, shareholders of Flexion will receive only $8.50 in cash and one non-tradable contingent value right (CVR) worth up to $8.00 per share in cash (assuming certain conditions are met) for each share of Flexion that |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ACBI, GTS, ADTN, COLB, DSPG, FLXN; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, COLB, FTSI, FLXN; Shareholders are Encouraged to Contact the FirmNEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Great Western Bancorp, Inc. (NYSE: GWB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to First Interstate BancSystem, Inc. Under the terms of the agreement, Great Western shareholders will receive 0.8425 shares of First Interstate Class A common stock for each Great Western |
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXNJuan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Flexion Therapeutics, Inc. ("FLXN" or the "Company") (FLXN) relating to its proposed acquisition by Pacira BioSciences, Inc. Under the terms of the agreement, FLXN shareholders will receive $8.50 in cash per share they own. |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
Earnings Preview: Flexion Therapeutics (FLXN) Q3 Earnings Expected to DeclineFlexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |